GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (OTCPK:RAONF) » Definitions » EV-to-EBITDA

Race Oncology (Race Oncology) EV-to-EBITDA : -12.09 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Race Oncology EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Race Oncology's enterprise value is $142.59 Mil. Race Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.79 Mil. Therefore, Race Oncology's EV-to-EBITDA for today is -12.09.

The historical rank and industry rank for Race Oncology's EV-to-EBITDA or its related term are showing as below:

RAONF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -153.55   Med: 0   Max: 0
Current: -12.32

RAONF's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs RAONF: -12.32

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Race Oncology's stock price is $1.45. Race Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.046. Therefore, Race Oncology's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Race Oncology EV-to-EBITDA Historical Data

The historical data trend for Race Oncology's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology EV-to-EBITDA Chart

Race Oncology Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial -0.86 -20.83 -79.64 -23.75 -13.33

Race Oncology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -23.75 - -13.33 -

Competitive Comparison of Race Oncology's EV-to-EBITDA

For the Biotechnology subindustry, Race Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Race Oncology's EV-to-EBITDA falls into.



Race Oncology EV-to-EBITDA Calculation

Race Oncology's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=142.588/-11.791
=-12.09

Race Oncology's current Enterprise Value is $142.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Race Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Race Oncology  (OTCPK:RAONF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Race Oncology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.45/-0.046
=At Loss

Race Oncology's share price for today is $1.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Race Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.046.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Race Oncology EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Race Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology (Race Oncology) Business Description

Traded in Other Exchanges
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a specialty pharmaceutical company. It is engaged in the development and marketing of pharmaceutical drugs for the treatment of Cancer. Its product includes Bisantrene, a cancer chemotherapy drug. Its operating segments include research into oncology drugs, Zantrene and the manufacturing and distribution of the drug for clinical trials.

Race Oncology (Race Oncology) Headlines